ICYMI, some of the content featured this week includes articles about how to choose a telemedicine vendor, the launch of an international COVID-19 dermatology registry, a study evaluating dupilumab’s durability versus cyclosporine in patients with atopic dermatitis, plus more.
Nivolumab plus talazoparib did not produce RECIST-based tumor responses in heavily pretreated patients with unresectable or metastatic melanoma.
In this week’s Pointers With Portela, the 208SkinDoc discusses the effectiveness of a minimalist anti-aging skin care routine for patients.
Researchers recently developed and validated the 3-question social comparison scale, which may be applicable outside of conditions such as eczema and psoriasis.
The WHO underscores the significance of addressing scabies as a neglected skin disease, especially in regions with limited health care access.
Addressing gender inequity in academic dermatology involves strengthening societies, celebrating female dermatologists, promoting leadership, and equitable representation, authors wrote.
The WHO underscores the significance of addressing scabies as a neglected skin disease, especially in regions with limited health care access.
David Rosmarin, MD, addresses the research gaps in recommendations for systemic therapies in atopic dermatitis in the latest guidelines.
Interim findings from the PROSPER study of mogamulizumab in adults with CTCL were recently presented orally.
Five experts delved into the latest updates to treatment guidelines and the updated label use for dupilumab for hand-foot AD.
In recognition of Rosacea Awareness Month, Dermatology Times is reviewing research and strides in rosacea treatment over the last decade.
